# GEM2017FIT (NCT03742297)

> Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

No report yet. It can be ordered.

- Drugs tested: daratumumab plus KRd; KRd
- Indication: older fit newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03742297
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: PETHEMA Foundation
- Conditions: Newly Diagnosed Multiple Myeloma
- Interventions: Lenalidomide.; Carfilzomib; Bortezomib; Daratumumab; Dexamethasone; Prednisone; Melphalan
- Enrollment: 462
- Primary outcome: Efficacy in terms of numbers of compleat responses

## Indexed commentary on GEM2017FIT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 23
- YouTube: 7
- Podcasts: 6
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gem2017fit-nct03742297

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03742297", "email": "<work email>"}; the inbox owner confirms by the emailed link.